SV2018005729A - Biomarcadores de copanlisib - Google Patents

Biomarcadores de copanlisib

Info

Publication number
SV2018005729A
SV2018005729A SV2018005729A SV2018005729A SV2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A
Authority
SV
El Salvador
Prior art keywords
respond
patients
progress
biomarkers
nhl
Prior art date
Application number
SV2018005729A
Other languages
English (en)
Inventor
Carol Pena
Li Liu
Jie Cheng
Karl Köchert
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2018005729A publication Critical patent/SV2018005729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

ESTA INVENCIÓN PROPORCIONA BIOMARCADORES BASADOS EN EL PERFIL DE EXPRESIÓN GÉNICA QUE PUEDE DISTINGUIRSE ENTRE PACIENTES QUE RESPONDEN Y/O TIENEN UNA MAYOR SUPERVIVENCIA LIBRE DE PROGRESIÓN Y PACIENTES QUE NO RESPONDEN Y/O TIENEN MENOR SUPERVIVENCIA LIBRE DE PROGRESIÓN A PARTIR DEL TRATAMIENTO CON COPANLISIB EN LINFOMA, QUE INCLUYE NHL INDOLENTE Y AGRESIVO Y CLL. LA PRESENTE INVENCIÓN SE REFIERE AL USO DE GENES DE BCR, PI3K, NFKB, IL6, PROCESOS INFLAMATORIOS Y ESTROMALES COMO BIOMARCADORES PREDICTIVOS PARA DIVERSOS CÁNCERES HUMANOS QUE INCLUYEN, ENTRE OTROS, NHL
SV2018005729A 2016-02-01 2018-08-07 Biomarcadores de copanlisib SV2018005729A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662289715P 2016-02-01 2016-02-01

Publications (1)

Publication Number Publication Date
SV2018005729A true SV2018005729A (es) 2018-12-05

Family

ID=57984907

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005729A SV2018005729A (es) 2016-02-01 2018-08-07 Biomarcadores de copanlisib

Country Status (16)

Country Link
US (1) US20190382839A1 (es)
EP (1) EP3411498A1 (es)
JP (1) JP2019512003A (es)
KR (1) KR20180104129A (es)
CN (1) CN109072307A (es)
AU (1) AU2017215096A1 (es)
BR (1) BR112018015783A2 (es)
CA (1) CA3012951A1 (es)
CL (1) CL2018002070A1 (es)
MA (1) MA43958A (es)
MX (1) MX2018009367A (es)
PH (1) PH12018501622A1 (es)
SG (2) SG10202007322PA (es)
SV (1) SV2018005729A (es)
TN (1) TN2018000272A1 (es)
WO (1) WO2017134030A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) * 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
CU24607B1 (es) * 2017-09-08 2022-06-06 Bayer Consumer Care Ag Sólido estable, liofilizado, que contiene copanlisib, útil para dilución y aplicaciones terapéuticas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ES2481672T3 (es) * 2003-07-17 2014-07-31 Pacific Edge Limited Marcadores para la detección del cáncer gástrico
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) * 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
DK3543355T3 (da) * 2013-06-20 2021-03-01 Taiho Pharmaceutical Co Ltd Fremgangsmåde til forudsigelse af terapeutisk effektivitet for pi3k/akt/mtor-hæmmer på basis af phlda1- eller pik3c2b-ekspression
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
PH12018501622A1 (en) 2019-06-03
BR112018015783A2 (pt) 2018-12-26
CL2018002070A1 (es) 2018-11-16
MA43958A (fr) 2018-12-12
WO2017134030A1 (en) 2017-08-10
KR20180104129A (ko) 2018-09-19
MX2018009367A (es) 2018-11-09
EP3411498A1 (en) 2018-12-12
TN2018000272A1 (en) 2020-01-16
JP2019512003A (ja) 2019-05-09
SG11201806512VA (en) 2018-08-30
AU2017215096A1 (en) 2018-08-09
CA3012951A1 (en) 2017-08-10
US20190382839A1 (en) 2019-12-19
SG10202007322PA (en) 2020-09-29
CN109072307A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
SV2018005729A (es) Biomarcadores de copanlisib
SV2018005730A (es) Biomarcadores para copanlisib
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
GT201700033A (es) Anticuerpos anti tigit
TWD190249S (zh) 通氣管
TWD185242S (zh) 集成的通用串行總線裝置延長線
AR095233A1 (es) Métodos y composiciones para el control de malezas
TWD169054S (zh) 轉接座
BR112016029675A2 (pt) dispositivos dilatadores nasais
GT201500249A (es) Terapia de combinación
TWD191254S (zh) 槓鈴護套
TWD189703S (zh) 泵浦
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
TWD190432S (zh) 鼻管
TWD173184S (zh) 秤
CO2017001842A2 (es) Artículo y método para mantener el flujo menstrual dentro de la vagina
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
TWD167131S (zh) 排水裝置之葉片用排水槽之部分
AR120118A2 (es) Anticuerpos anti tigit
TWD186713S (zh) 拖鞋之部分
TWD186711S (zh) 拖鞋之部分
TWD183722S (zh) 拖鞋
TWD188583S (zh) 身體刷
TWD179743S (zh) 照護用廁所
TWD182616S (zh) 拖鞋